Interferon-γ +874A/T polymorphism associated with *Toxoplasma gondii* seropositivity in HIV patients

Sri Haryati1,2,3, Afiono Agung Prasetyo1,4*, Ratna Sariyatun1,2, Yulia San1,2,3, Murkati1,2,3

1A-Infection, Genomic, Immunology and Cancer Research Group, Sebelas Maret University, Jl. Ir. Satami 36A, Surakarta, Indonesia
2Center of Biotechnology and Biodiversity Research and Development, Sebelas Maret University, Jl. Ir. Satami 36A, Surakarta, Indonesia
3Department of Parasitology, Faculty of Medicine, Sebelas Maret University, Jl. Ir. Satami 36A, Surakarta, Indonesia
4Department of Microbiology, Faculty of Medicine, Sebelas Maret University, Jl. Ir. Satami 36A, Surakarta, Indonesia

**ARTICLE INFO**

**ABSTRACT**

**Objective:** To investigate the association of polymorphisms in genes that code for interferon-γ (IFN-γ) and interleukin-10 (IL-10), which play important roles in *Toxoplasma gondii* (*T. gondii*) infection, with the occurrence of *T. gondii* co-infection in HIV patients.

**Methods:** The IFN-γ +874A/T and IL-10 -1082A/G polymorphism statuses of 306 HIV seropositive samples were characterized using PCR. The polymorphism statuses were analyzed together with the clinical data for each patient.

**Results:** Immunoglobulin M anti-*T. gondii* seropositivity was associated with high IL-10 levels [adjusted odds ratio (OR): 0.4, 95% confidence intervals (CI): 0.181–0.825; *P* = 0.014], but not with either the IL-10 -1082A/G or IFN-γ +874A/T polymorphism. In addition, the IFN-γ +874A allele was associated with immunoglobulin G (IgG) anti-*T. gondii* seropositivity (OR: 1.5, 95% CI: 1.043–2.193; *P* = 0.029). In patients with CD4+ T cell levels ≥ 200 cells/µL, the IFN-γ +874 AA genotype was associated with IgG anti-*T. gondii* seropositivity (adjusted OR: 2.5, 95% CI: 1.278–4.950; *P* = 0.008).

**Conclusions:** The IFN-γ +874A/T polymorphism is associated with IgG anti-*T. gondii* seropositivity. This polymorphism might be useful to predict the susceptibility of HIV patients to toxoplasmosis.

1. Introduction

*Toxoplasma gondii* (*T. gondii*) is the most prevalent and successful intracellular protozoan parasite worldwide[1,2]. This parasite is globally distributed, appearing as a long-lasting persistent infection in 30%–80% of the global human population and it is more prevalent in tropical areas, such as Indonesia[3,4]. *T. gondii* infection is asymptomatic in healthy people. However, this infection is life-threatening in HIV patients, in whom a latent infection with this parasite is commonly reactivated due to the immunodeficiency[4,5]. Notably, *T. gondii* has emerged as one of the most common opportunistic infections associated with AIDS during the past decade, reflecting the prevalence of latent infection in HIV-infected patients, which ranges from 3% to 97%[6,6]. In most cases, toxoplasma encephalitis is the most common manifestation of this disease and represents a leading cause of death among HIV patients. Toxoplasma encephalitis affects 50% of patients in Europe and Africa during the pre-highly active anti-retroviral therapy era[7]. The advent of highly active anti-retroviral therapy has decreased the occurrence of *T. gondii*-related manifestations in HIV patients[7], though reactivation remains a clinical challenge once a patient develops resistance.

Interferon-γ (IFN-γ) and interleukin-10 (IL-10) are two vital immune system cytokines secreted in response to *T. gondii* infection[2,3,8]. IFN-γ is the principal cytokine for host defense against *T. gondii*[8]. In contrast, IL-10 plays a key role in the regulation of inflammatory responses and cell-mediated immunity against this parasite, such as the inhibition of the production of cytokines required for the optimal production of IFN-γ, including tumor necrosis factor-α, IL-1, and IL-12[2,3,9,12]. The balance of the pro- and anti-inflammatory responses (IFN-γ and IL-10, respectively) is important for host survival[3,13]; IL-10 deficiency impairs immune homeostasis in response to infection-induced immunopathology, whereas high IL-10 production represses the immunity against the...
parasite, including IFN-γ-mediated responses, thereby enhancing the susceptibility to the progression of *T. gondii* infection[9].

Host genetic variations influence both IFN-γ and IL-10 production and are involved in various inflammatory and infectious diseases, such as *T. gondii* infection[14]. A single nucleotide polymorphism has been identified in the first intron of the IFN-γ gene at position +874A/T (rs2430561) located on chromosome 12q24.1. This mutation modulates the binding of nuclear factor-κB, thereby causing high (TT), intermediate (TA), or low (AA) IFN-γ production[15-18]. In addition, single nucleotide polymorphism-1082A/G (rs800896) in the IL-10 gene promoter might influence IL-10 transcription and secretion[19,20]. The -1082G allele is associated with a higher IL-10 serum concentration[21], whereas the -1082A allele is associated with lower IL-10 production[22]. Although both IFN-γ and IL-10 are crucial in *T. gondii* infection, the influence of IFN-γ and IL-10 polymorphisms on *T. gondii* infection is poorly understood. Here, we examined the influence of IFN-γ +874A/T and IL-10 -1082A/G polymorphisms on the susceptibility of HIV-infected patients to *T. gondii* infection.

2. Materials and methods

2.1. Study population

Since 2009, our research group has performed a molecular epidemiology study of human blood-borne viruses based on the collection of epidemiological data and blood samples from high-risk communities, such as drug-abusing inmates in prisons and jails, men having sex with men in Surakarta and the surrounding cities, commercial sex workers, injection drug users and people who have heterosexual contact with HIV-positive partners in Central Java, Indonesia[23,24]. During 2010-2012, 306 HIV-positive samples were collected. Blood samples were obtained from all patients and subjected to routine hematological and CD4+ T cell testing, the detection of immunoglobulin M (IgM) and immunoglobulin G (IgG) anti-*T. gondii* antibodies, and IFN-γ and IL-10 levels, as described previously[23-27]. Approval was obtained from the institutional ethical committee review boards of the Faculty of Medicine of Sebelas Maret University and Dr. Moewardi (General Hospital, Central Java Province, Indonesia). Written informed consent was obtained from each individual participating in the study. All procedures were conducted according to the principles of the Declaration of Helsinki.

2.2. Detection of IFN-γ +874A/T and IL-10 -1082A/G polymorphisms

Genomic DNA from each patient was isolated from peripheral blood using a high pure PCR template preparation kit (Roche Diagnostics, Mannheim, Germany). The IFN-γ +874A/T and IL-10 -1082A/G polymorphisms were genotyped via PCR using the FastStart HiFi PCR System dNTPack (Roche) with primer pairs previously described for IFN-γ +874A/T and IL-10 -1082A/G polymorphisms[28,29]. To avoid false-negative results, an internal control primer amplifying a 429-bp region of the human growth hormone gene was used for all PCR reactions[26]. The PCR products were subjected to electrophoresis in ethidium bromide-stained 3% agarose gels for 30 min at 100 V. The IFN-γ +874A/T and IL-10 -1082A/G allele frequencies were estimated using the direct counting method.

2.3. Statistical analysis

The Chi-square test was used to assess the Hardy-Weinberg equilibrium (HWE) of the IFN-γ +874A/T and IL-10 -1082A/G genotype distributions in the study population. The Chi-square test, Fisher’s exact test and Kolmogorov-Smirnov test were used to analyze categorical variables. Logistic regression was used to reveal associations between polymorphism status and patient susceptibility to *T. gondii* infection. All data were analyzed using a 95% confidence interval (CI) and a two-tailed P value of < 0.05 was considered to indicate significant differences. All statistical analyses were performed using SPSS software version 21 (IBM Corp, Armonk, NY, USA).

3. Results

3.1. Study population

HIV-positive samples were collected from 174 (56.9%) males and 132 (43.1%) females; the patients were aged 19–72 years (Table 1). Some patients (31.4%; 96/306) were severely immunodeficient, with CD4+ T cell counts < 200 cells/µL[30]. Among the subjects, patients aged ≤ 30 years tended to have a high CD4+ T cell percentage (> 28%) [odds ratio (OR) 2.0, 95% CI 1.096–3.536; P = 0.022] and a CD4+ T cell count > 500 cells/µL (OR 2.1, 95% CI 1.252–3.630; P = 0.005).

| Characteristics                  | n (%)          |
|----------------------------------|----------------|
| Gender                           | Male 174 (56.9) |
|                                  | Female 132 (43.1) |
| Mean age ± SD in years           | 35.9 ± 8.9 |
| Age category in years            | ≤ 30 78 (25.5) |
|                                  | 31–40 155 (50.6) |
|                                  | 41–50 51 (16.7) |
|                                  | > 50 22 (7.2) |
| Risk status                      | High-risk couples 104 (34.0) |
|                                  | IDUs 54 (17.7) |
|                                  | CSWs 35 (11.4) |
|                                  | Customers of CSWs 89 (29.1) |
|                                  | MSM 24 (7.8) |
| Anemia*                          | 160 (52.3) |
| Erythrocyte (×10^6/µL)           | < 4.4M/< 3.9F 241 (78.8) |
|                                  | 4.4–5.7M/3.9–5.0F 61 (19.9) |
|                                  | > 5.7M> 5.0F 4 (1.3) |
| Leukocyte (×10^9/µL)             | < 3.9M< 3.7F 52 (17.0) |
|                                  | 3.9–11.1M< 7.9–5.9F 242 (79.1) |
|                                  | > 11.1M> 9.5F 12 (3.9) |
| Hematocrit (%)                   | < 33 79 (25.8) |
|                                  | 33–45 222 (72.6) |
|                                  | > 45 5 (1.6) |
| CD4+ T cell (%)                  | < 14 118 (38.5) |
|                                  | 14–28 122 (39.9) |
|                                  | > 28 66 (21.6) |
| CD4+ T cell (cells/µL)           | < 200 96 (31.4) |
|                                  | 200–500 112 (36.6) |
|                                  | > 500 98 (32.0) |
| IFN-γ (pg/mL)                    | ≤ 10 289 (94.4) |
|                                  | >10 17 (5.6) |
| IL-10 (pg/mL)                    | ≤ 10 207 (67.6) |
|                                  | >10 99 (32.4) |

*: Patients were considered anemic when the hemoglobin levels were < 13.3 g/dL (M) and < 11.8 g/dL (F). M: Male; F: Female; IDUs: Injection drug users; CSWs: Commercial sex workers; MSM: Men have sex with men.
3.2. IgM/IgG anti-T. gondii seropositivity

In total, 22.5% (69/306) and 31.7% (97/306) of patients were IgM and IgG anti-T. gondii seropositive, respectively. The proportion of IgM and IgG anti-T. gondii positivity differed by age (P < 0.001 and P = 0.002, respectively); IgM anti-T. gondii positivity was less frequent in patients aged ≤ 30 years, whereas the IgG anti-T. gondii positivity was more common in older patients (Tables 2 and 3). In addition, IgM anti-T. gondii, but not IgG, was associated with CD4+ T cell levels (Table 3). However, the rate of IgM anti-T. gondii seropositivity was differentially associated with CD4+ T cell count and percentages were discordant. While IgM anti-T. gondii positivity tended to be negatively associated with CD4+ T cell percentage, it was less common in patients with CD4+ T cell < 100 cells/µL (Tables 2 and 3). Furthermore, the rates of IgM and IgG anti-T. gondii seropositivity did not correlate with the plasma IFN-γ levels (P = 0.771 and P = 0.069, respectively), whereas a significant association between IgM anti-T. gondii seropositivity and the IL-10 levels was observed (Table 3).

Table 2

Distribution of IgM (N = 69) and IgG (N = 97) anti-T. gondii seropositivity with respect to the clinical status of the HIV patients. n (%).

| Characteristics | IgM anti-T. gondii (+) | IgG anti-T. gondii (+) |
|-----------------|-----------------------|-----------------------|
| Gender          |                       |                       |
| Male            | 37 (53.6)             | 64 (66.0)             |
| Female          | 32 (46.4)             | 33 (34.0)             |
| Age in years    |                       |                       |
| ≤ 30            | 78 (45.8)             | 13 (13.4)             |
| 31–40           | 155 (63.2)            | 59 (60.8)             |
| 41–50           | 51 (23.2)             | 14 (14.5)             |
| > 50            | 22 (8.7)              | 11 (11.3)             |
| CD4+ T cell percentage |                   |                       |
| < 14            | 118 (36.2)            | 37 (38.1)             |
| 14-28           | 122 (39.5)            | 35 (36.1)             |
| > 28            | 66 (4.3)              | 25 (25.8)             |
| CD4+ T cell count (cells/µL) |                  |                       |
| < 200           | 96 (28.9)             | 28 (28.9)             |
| 200–500         | 112 (37.1)            | 36 (37.1)             |
| > 500           | 98 (33.0)             | 33 (34.0)             |
| CD4+ T cell < 100 cells/µL |       |                       |
| ≤ 10            | 289 (95.7)            | 95 (97.9)             |
| > 10            | 17 (4.3)              | 2 (2.1)               |
| IFN-γ (pg/mL)   |                       |                       |
| ≤ 10            | 207 (75.4)            | 69 (71.1)             |
| > 10            | 99 (24.6)             | 28 (28.9)             |

3.3. IFN-γ +874A/T and IL-10 -1082A/G polymorphisms

In total, 49.0% (150/306), 34.0% (104/306) and 17.0% (52/306) of patients harbored IFN-γ +874 AA, AT, and TT genotypes, respectively, resulting in A and T allele frequencies of 0.660 and 0.340, respectively. In addition, IL-10 -1082 AA, AG and GG genotypes were observed in 28.4% (87/306), 58.2% (178/306) and 13.4% (41/306) of patients, respectively, with A and G allele frequencies of 0.575 and 0.425, respectively. The distribution of IFN-γ +874A/T (P < 0.001) and IL-10 -1082A/G (P = 0.001) genotype polymorphisms in HIV-positive patients deviated from the expected frequencies for HWE. Interestingly, the IFN-γ +874T allele most commonly appeared with the IL-10 -1082A allele (OR = 1.7, 95% CI 1.327–2.168; P < 0.001) and less commonly appeared with the IL-10 -1082G allele (OR = 0.6, 95% CI 0.461–0.753; P < 0.001). Similarly, individuals bearing the IFN-γ +874T allele (AT/TT) frequently carried the IL-10 -1082A allele (AA/AG) (OR = 2.5, 95% CI 1.253–5.088; P = 0.008), whereas patients with the IFN-γ +874A allele (AA/AT) commonly harbored the IL-10 -1082G allele (AG/GG) (OR = 4.7, 95% CI 2.525–8.797; P < 0.001).

Table 3

Factors associated with IgM and IgG anti-T. gondii seropositivity in HIV patients.

| Characteristics | IgM anti-T. gondii (+) | IgG anti-T. gondii (+) |
|-----------------|-----------------------|-----------------------|
| Age in years    |                       |                       |
| ≤ 30            | 0.1 (0.048–0.386)     | < 0.001               |
| 31–40           | 1.8 (1.065–3.198)     | 0.028                 |
| > 50            | 1.0 (0.534–2.010)     | -                     |
| Gender/male     |                       |                       |
| Male            | -                     |                       |
| Female          | -                     |                       |
| CD4+ T cell     |                       |                       |
| < 100 cells/µL  | 0.2 (0.037–0.823)     | 0.015                 |
| < 200 cells/µL  | 2.1 (1.198–3.549)     | 0.008                 |
| > 500 cells/µL  | 6.0 (0.336–1.137)     | 0.120                 |

aOR: Adjusted odds ratio.

3.4. Association of IFN-γ +874A/T and IL-10 -1082A/G polymorphisms with cytokine levels, CD4+ T cell counts and IgM/IgG anti-T. gondii seropositivity

Neither the IFN-γ +874A/T nor the IL-10 -1082A/G genotype distribution were correlated with the IFN-γ (P = 0.182 and P = 0.560, respectively) or IL-10 levels (P = 0.621 and P = 0.519, respectively). In contrast, the proportion of IFN-γ +874A/T and IL-10 -1082A/G genotypes was significantly correlated with the CD4+ T cell percentage (P = 0.001 and P = 0.037, respectively) and CD4+ T cell count (P = 0.003 and P = 0.001, respectively). The IFN-γ +874A allele was associated with a low CD4+ T cell count (< 200 cells/µL) (OR 1.5, 95% CI 1.020–2.146; P = 0.039) and percentage (< 14%) (OR 1.8, 95% CI 1.247–2.544; P = 0.002). A low CD4+ T cell count was also associated with the IL-10 -1082A allele (OR 1.9, 95% CI 1.307–2.675; P < 0.001).

The IFN-γ +874A/T and IL-10 -1082A/G allele frequencies did not correlate with IgM anti-T. gondii seropositivity (Table 4) in either males (P = 0.800 and P = 0.216, respectively) or females (P = 0.266 and P = 0.155, respectively), whereas the IFN-γ +874A allele was associated with a higher likelihood to harbor IgG anti-T. gondii seropositivity (Table 4). Independent analyses of the male and female groups showed that the rate of IgG anti-T. gondii seropositivity was only correlated with the IFN-γ +874A allele frequencies in males (P = 0.014), but not in females (P = 0.965). A multivariate analysis of the male group considering the age, risk status and clinical condition of the patient showed that the IFN-γ +874A/T genotype did not significantly contribute to IgG anti-T. gondii seropositivity (P = 0.086).

To overcome pitfalls due to potentially false IgM/IgG anti-T. gondii seronegativity in immunosuppressed patients, a analysis of a group of patients with CD4+ T cell counts ≥ 200 cells/µL (n = 210)
was conducted. Similar to the analysis of the overall group, the IFN-γ +874A/T IL-10 -1082A/G genotypes and alleles according to the IgM and IgG anti-T. gondii seropositivity of the HIV patients.

### Table 4

| Polymorphism | IgM anti-T. gondii (+) (n = 69) | IgG anti-T. gondii (+) (n = 97) |
|--------------|---------------------------------|---------------------------------|
|              | Frequencies OR (95% CI) P       | Frequencies OR (95% CI) P       |
| IFN-γ +874 genotypes | TT (n = 52) | 23.2 (16/69) | 1.0 | 0.260a |
|                | AT (n = 104) | 29.0 (20/69) | 0.5 | 0.249–1.151 | 30.9 (30/97) | 1.4 | 0.624–2.925 |
|                | AA (n = 150) | 47.8 (33/69) | 0.6 | 0.314–1.284 | 56.7 (55/97) | 1.9 | 0.934–3.987 |
|                | AA (n = 150) | 47.8 (33/69) | 1.0 |               | 56.7 (55/97) | 1.0 |               |
|                | AT + TT (n = 156) | 52.2 (36/69) | 1.1 | 0.622–1.819 | 43.3 (42/97) | 0.6 | 0.392–1.034 |
|                | TT (n = 52) | 23.2 (16/69) | 1.0 |               | 12.4 (12/97) | 1.0 |               |
|                | AA + AT (n = 254) | 76.8 (53/69) | 0.6 | 0.306–1.150 | 87.6 (85/97) | 1.7 | 0.836–3.362 |
| IFN-γ +874 alleles | A (n = 404) | 62.3 (86/138) | 0.8 | 0.547–1.203 | 72.2 (140/194) | 1.5 | 1.043–2.193 |
|                | T (n = 208) | 37.7 (52/138) | 1.2 | 0.831–1.828 | 27.8 (54/194) | 0.7 | 0.456–0.959 |
| IL-10 -1082 genotypes | GG (n = 265) | 76.8 (53/69) | 0.6 | 0.306–1.150 | 87.6 (85/97) | 1.7 | 0.836–3.362 |
|                | AA (n = 178) | 24.6 (16/69) | 0.2 | 0.074–0.368 | 66.0 (64/97) | 2.0 | 0.897–4.444 |
|                | AA (n = 87) | 52.2 (36/69) | 1.1 | 0.516–2.356 | 24.7 (24/97) | 1.4 | 0.564–3.254 |
|                | AA (n = 87) | 52.2 (36/69) | 1.0 |               | 24.7 (24/97) | 1.0 |               |
|                | AA + GG (n = 219) | 47.8 (33/69) | 0.3 | 0.143–0.442 | 75.3 (73/97) | 1.3 | 0.759–2.270 |
|                | GG (n = 41) | 23.2 (16/69) | 1.0 |               | 9.3 (9/97) | 1.0 |               |
|                | AA + AG (n = 265) | 76.8 (53/69) | 0.6 | 0.306–1.150 | 90.7 (88/97) | 1.8 | 0.808–3.866 |
| IL-10 -1082 alleles | A (n = 352) | 64.5 (89/138) | 1.5 | 0.984–2.158 | 57.7 (112/194) | 1.0 | 0.718–1.430 |
|                | G (n = 260) | 35.5 (49/138) | 0.7 | 0.463–1.016 | 42.3 (82/194) | 1.0 | 0.699–1.393 |

a Frequencies of genotypes among patients with CD4+ T cell counts < 14% and those with higher levels were compared using the Chi-square test for 3 × 2 contingency tables; b Frequencies of genotypes between cases and controls were compared using the Chi-square test for 2 × 2 contingency tables to analyze AA and TT genotypes with respect to AT + TT and AT + AA, respectively.

**4. Discussion**

Due to the high risk of the fatal reactivation of past *T. gondii* infection in immunocompromised individuals, the detection and monitoring of anti-*T. gondii* antibodies has been recommended for newly diagnosed HIV-positive patients and prophylaxis should be considered in patients with CD4+ T cell counts < 200 cells/µL. However, diagnosis is difficult because clinical manifestations are non-specific and anti-*T. gondii* antibody concentrations are low. Furthermore, diagnosis is even more challenging in low-resource countries and reinfection in HIV patients will be useful to prevent the incidence of this disease.

The level of CD4+ T cells, which are essential regulators of the immune reaction during toxoplasmosis[3,8,35], has been suggested as an indicator for the susceptibility to reactivation[36]. The risk for latent *T. gondii* infection reactivation increases as CD4+ T cell counts below 100 cells/µL and the incidence of *T. gondii* seropositivity is also higher in HIV-infected individuals with CD4+ T cell counts of 200–499 cells/µL than in individuals with counts > 500 cells/µL[36,37]. Similarly, the results of this study showed that IgM anti-*T. gondii* seropositivity is more common in patients with 200–500 CD4+ T cells/µL than in patients with > 500 CD4+ T cells/µL; furthermore, the frequency of IgM anti-*T. gondii* seropositivity gradually decreases with the CD4+ T cell percentage increases. However, IgG anti-*T. gondii* seropositivity did not correlate with the CD4+ T cell levels[38-40]. Interestingly, we observed that the rate of IgM anti-*T. gondii* was significantly lower in patients with CD4+ T cell counts < 100 cells/µL than in patients with higher CD4+ T cell counts. This finding likely indicates false IgM anti-*T. gondii* seroconversion resulting from the severe immunodeficiency of patients with CD4+ T cell counts < 100 cells/µL, which impairs the production of IgM anti-*T. gondii*[5,40]. Unfortunately, we could not confirm the presence of *T. gondii* infection in these patients. Further studies should analyze the appropriateness of IgM anti-*T. gondii* testing in patients with severe immunosuppression because these tests might underestimate the diagnosis of *T. gondii* co-infection in HIV patients.

In our study, the rate of IgM anti-*T. gondii* seropositivity was lower than that of IgG anti-*T. gondii* seropositivity, which is consistent with previous reports[40,41]. The proportions of both antibodies were the smallest in patients aged ≤ 30 years and increased in older patients. These results are consistent with previous studies showing that the prevalence of the *T. gondii* serological marker increases with age[42-45]. These results reflect higher CD4+ T cell counts in young subjects and lower CD4+ T cell counts in older patients[25,43]. Moreover, older individuals have potentially been exposed to the parasite for a longer time, explaining the higher serological prevalence observed in this group[46].

The IL-10 -1082A/G alleles and IgM/IgG anti-*T. gondii* seropositivity were not correlated in the overall population, whereas the IFN-γ +874A allele was associated with a higher likelihood of harboring IgG anti-*T. gondii*. To examine potential pitfalls in analyzing IgM and IgG anti-*T. gondii* due to the aforementioned false seronegativity in immunosuppressed patients, we analyzed the association between both polymorphisms and serological markers of *T. gondii* in patients with CD4+ T cell counts ≥ 200 cells/µL. In this group, patients carrying the IFN-γ +874 AA genotype were...
more susceptible to IgG anti-T. gondii seropositivity than patients carrying other genotypes. Thus, the IFN-γ+874A/T polymorphism status might be useful to predict the likelihood of IgG anti-T. gondii positivity in HIV patients. In addition, the results of the present study showed no association between the IFN-γ +874A/T and IL-10 -1082A/G polymorphisms and IFN-γ and IL-10 levels, respectively. This lack of association might reflect the fact that the HIV infection influences the expression of IFN-γ and IL-10[47,48], thereby disguising the effect of either the IFN-γ +874A/T or IL-10 -1082A/G polymorphism on the cytokine levels.

To the best of our knowledge, this is the first study to report the rate of the IFN-γ +874A/T polymorphism in Indonesia. The results of the present study also enriched the data concerning the IL-10 -1082A/G polymorphism in Indonesia and Southeast Asia, which remain limited[27]. The results of the present study might provide further insight into the distribution of polymorphisms in this area, which is beneficial because both polymorphisms have been associated with infectious diseases[15,27,35]. This study also contributed data on IgM and IgG anti-T. gondii seropositivity in HIV-infected patients in Indonesia.

The present study has several limitations. First, T. gondii infection was defined based on the detection of IgM and IgG anti-T. gondii. However, the titers of these antibodies were unknown. As a limitation of serological testing, the false negativity reflecting impaired antibody production in immunodeficient individuals and the window period of the infection could not be excluded. Second, the distribution of both IFN-γ +874A/T and IL-10-1082A/G genotype polymorphisms did not comply with HWE, reflecting the fact that only HIV patients were enrolled in the present study. Thus, our results do not represent the distribution in the general population. This limitation should be a concern because this specific enrollment potentially affects the associations found in the present study[49]. In addition, risk factors for T. gondii infection, such as the clinical stage of HIV infection and behavioral history of each patient (e.g., contact with cats and the consumption of undercooked meats), were not considered whereas these parameters might confound the observed associations. Nevertheless, this study showed that the IFN-γ +874A/T polymorphism might predict the susceptibility of HIV patients for the development of toxoplasmosis. Due to the aforementioned limitations, further research is needed to confirm the findings presented herein.

In conclusion, in HIV patients with CD4+ T cell counts ≥ 200 cells/µL, the IFN-γ +874 AA genotype is associated with increased risk of IgG anti-T. gondii positivity. Characterizing the IFN-γ +874A/T polymorphism status of HIV patients might be useful to predict susceptibility to the development of toxoplasmosis.

**Conflict of interest statement**

We declare that we have no conflict of interest.

**Acknowledgments**

This work was financially supported in part by grants from the Indonesian Directorate of Higher Education (440/SP2H/PP/DP 2010, No. 505/SP2H/PL/Dit. Litabmas/VI/2011, No. 197/SP2H/PL/Dit. Litabmas/IV/2012, and No. 077/SP2H/PL/Dit.Litabmas/V/2013) and the Indonesian Directorate of Higher Education-APBN/DIPA UNS (No. 2342/UN27.16/PN/2012, No. 159a/UN27.11/PN/2013, No. 165/UN27.11/PN/2013, No. 267a/UN27.16/PN/2013, No. 501/UN27.11/PN/2014, No. 853/UN27.11/PN/2014, and No. 339/UN27.11/PL/2015).

**References**

[1] Bilgrami M, O’Keefe P. Neurologic diseases in HIV-infected patients. *Handb Clin Neurol* 2014; 121: 1321-44.

[2] Tait ED, Hunter CA. Advances in understanding immunity to *Toxoplasma gondii*. *Mem Inst Oswaldo Cruz* 2009; 104(2): 201-10.

[3] Denkers EY. From cells to signaling cascades: manipulation of innate immunity by *Toxoplasma gondii*. *FEMS Immunol Med Microbiol* 2003; 39(3): 193-203.

[4] Remington JS, McLeod R, Thulliez P, Desmonts G. Toxoplasmosis. In: Remington JS, Klein JO, Wilson CB, Baker CJ, editors. *Infectious diseases of the fetus and newborn infant*. 6th ed. Philadelphia: Elsevier Saunders; 2006, p. 947-1091.

[5] Montoya JG, Liesenfeld O. Toxoplasmosis. *Lancet* 2004; 363: 1965-76.

[6] Nissapatorn V. Toxoplasmosis in HIV/AIDS: a living legacy. *Southeast Asian J Trop Med Public Health* 2009; 40(6): 1158-78.

[7] Alkali NH, Bwala SA, Nyandaiti YW, Danesi MA. NeuroAIDS in sub-Saharan Africa: a clinical review. *Ann Afr Med* 2013; 12(1): 1-10.

[8] Sarciron ME, Gherardi A. Cytokines involved in Toxoplasmic encephalitis. *Scand J Immunol* 2000; 52(6): 534-43.

[9] Butler NS, Harris TH, Blader II. Regulation of immunopathogenesis during *Plasmodium* and *Toxoplasma* infections: more parallels than distinctions? *Trends Parasitol* 2013; 29(12): 593-602.

[10] Lu F, Huang S, Kasper LH. Interleukin-10 and pathogenesis of murine ocular toxoplasmosis. *Infect Immun* 2003; 71(12): 7159-63.

[11] Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. *Annu Rev Immunol* 2001; 19: 683-765.

[12] Rezende-Oliveira K, Silva NM, Mineo JR, Rodrigues Junior V. Cytokines and chemokines production by mononuclear cells from parturient women after stimulation with live *Toxoplasma gondii*. *Placenta* 2012; 33(9): 682-7.

[13] Lang C, Algner M, Beinert N, Gross U, Lüder CGK. Diverse mechanisms employed by *Toxoplasma gondii* to inhibit IFN-γ-induced major histocompatibility complex class II gene expression. *Microbes Infect* 2006; 8(8): 1994-2005.

[14] Ben-Selma W, Harizi H, Bougmiza I, Hannachi N, Ben Kahla I, Zaieni R, et al. Interferon gamma +874T/A polymorphism is associated with susceptibility to active pulmonary tuberculosis development in Tunisian patients. *DNA Cell Biol* 2011; 30(6): 379-87.

[15] Albuquerque MC, Aleixo AL, Benchimol EI, Leandro AC, das Neves PM, et al. Polymorphism of interferon-gamma gene at position +874 and clinical characteristics of chronic hepatitis C. *Transl Res* 2006; 148(3): 128-33.

[16] Henao MI, Montes C, París SC, García LF. Cytokine gene polymorphisms in Colombian patients with different clinical presentations of tuberculosis. *Tuberculosis (Edinb)* 2006; 86(1): 11-9.

[17] López-Maderuelo D, Arnalich F, Serantes R, González A, Codocoe R, Madero R, et al. Interferon-gamma and interleukin-10 gene polymorphisms in pulmonary tuberculosis. *Am J Respir Crit Care Med* 2003; 167(7): 970-5.

[18] Chand-Bhayal A, Krishnaveni D, Pandu-Ranga-Rao K, Prabhakar B, Vidyasagar A, Murali-Krishna B, et al. Association of interleukin-10 promoter polymorphism (-1082 G/A) and gastric cancer in andhra
pradesh population of South India. *Iran J Cancer Prev* 2012; 5(3): 117-23.

[20] Ma L, Li S, Lu Y, Zhang X, Zhao J, Qin X. A pooled analysis of the IL-10 -1082 A/G polymorphism and the nasopharyngeal carcinoma susceptibility. *Ear Arch Otorhinolaryngol* 2014; doi: 10.1007/s00405-014-3465-9.

[21] Lesiak A, Zakrzewski M, Przybyłowska K, Rogowski-Tylman M, Wozniacka A, Narbutt J. Atopic dermatitis patients carrying G allele in -1082 G/A IL-10 polymorphism are predisposed to higher serum concentration of IL-10. *Arch Med Sci* 2014; 10(6): 1239-43.

[22] Yanamandra K, Boggs P, Loggins J, Baier RJ. Interleukin-10 -1082 G/A polymorphism and risk of death or bronchopulmonary dysplasia in ventilated very low birth weight infants. *Pediatr Pulmonol* 2005; 39(5): 426-32.

[23] Prasetyo AA, Dirgahayu P, Sari Y, Hudiyono H, Kaigeysna S. Molecular epidemiology of HIV, HBV, HCV, and HTLV-1/2 in drug abuser inmates in central Javanese prisons, Indonesia. *J Infect Dev Ctries* 2013; 7(6): 453-67.

[24] Prasetyo AA, Ariapramuda ER, Kindi EA, Dirgahayu P, Sari Y, Dharmawan R, et al. Men having sex with men in Surakarta, Indonesia: demographics, behavioral characteristics and prevalence of blood borne pathogens. *Southeast Asian J Trop Med Public Health* 2014; 45(5): 1032-47.

[25] Prasetyo AA, Zaini KUN. Establishing mean CD4+ T cell values among healthy Javanese adults in Indonesia. *Southeast Asian J Trop Med Public Health* 2015; 46(4): 662-8.

[26] Prasetyo AA, Sariyutan R, Reviono, Sari Y, Hudiyono, Haryati S, et al. The APOBEC3B deletion polymorphism is associated with prevalence of hepatitis B virus, hepatitis C virus, Torque Teno virus, and *Toxoplasma gondii* co-infection among HIV-infected individuals. *J Clin Virol* 2015; 70: 67-71.

[27] Prasetyo AA, Nurfitria FB, Adnan ZA, Redhono D, Sari Y, Hudiyono. The -1082 A allele of the interleukin-10 single nucleotide polymorphism -1082 G/A is associated with hepatitis virus co-infection in Indonesian Javanese HIV patients. *Int J Interferon Cytokine Mediator Res* 2015; 7: 1-7.

[28] Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. *Hum Immunol* 2000; 61(9): 863-6.

[29] Korachi M, Pravica V, Barson AJ, Hutchinson IV, Drucker DB. Interleukin 10 genotype as a risk factor for sudden infant death syndrome: determination of IL-10 genotype from wax-embedded postmortem samples. *FEMS Immunol Med Microbiol* 2004; 42(1): 125-9.

[30] World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva: World Health Organization; 2007. [Online] Available from: http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf [Accessed on 21st June, 2015]

[31] Ganiem AR, Dian S, Indriati A, Chaidir L, Wisaksana R, Sturm P, et al. Cerebral toxoplasmosis mimicking subacute meningitis in HIV-infected patients; a cohort study from Indonesia. *PLoS Negl Trop Dis* 2013; 7(1): e1994.

[32] Li ZH, Guo FY, Wang QZ, Cui J. Intracranial inflammatory granuloma caused by toxoplasmosis. *Pathog Glob Health* 2014; 108(5): 255-9.

[33] Terazawa A, Muljono R, Susanto L, Margono SS, Konishi E. High *Toxoplasma* antibody prevalence among inhabitants in Jakarta, Indonesia. *Jpn J Infect Dis* 2003; 56(3): 107-9.

[34] Indonesian National AIDS Commission. Republic of Indonesia country report on the follow up to the declaration of commitments on HIV/AIDS (UNGASS) reporting period 2010-2011. Jakarta: Indonesian National AIDS Commission; 2012 [Online] Available from: http://www.unaids.org/sites/default/files/documents/cc_ID_Narrative_Report.pdf [Accessed on 21st June, 2015]

[35] Jankovic D, Kugler DG, Sher A. IL-10 production by CD4+ effector T cells: a mechanism for self-regulation. *Microsoual Immunol* 2010; 3(3): 239-46.

[36] Robert-Gangneux F, Dardé ML. Epidemiology of and diagnostic strategies for toxoplasmosis. *Clin Microbiol Rev* 2012; 25(2): 264-96.

[37] Falusi O, French AL, Seaberg EC, Tien PC, Watts DH, Minkoff H, et al. Prevalence and predictors of *Toxoplasma* seropositivity in women with and at risk for human immunodeficiency virus infection. *Clin Infect Dis* 2002; 35(11): 1414-7.

[38] Nissapatorn V, Kamarulzaman A, Ini T, Tan LH, Rohela M, Norliza A, et al. Seroprevalence of toxoplasmosis among HIV-infected patients and healthy blood donors. *Med J Malaysia* 2002; 57(3): 304-10.

[39] Nissapatorn V, Lee CK, Cho SM, Rohela M, Anuur AK, Quek KF, et al. Toxoplasmosis in HIV/AIDS patients in Malaysia. *Southeast Asian J Trop Med Public Health* 2003; 34(Suppl 2): 80-5.

[40] Ogozina D, Onyemelukwe GC, Musa BO, Obiako RO. Seroprevalence of IgM and IgG antibodies to *Toxoplasma* infection in healthy and HIV-positive adults from Northern Nigeria. *J Infect Dev Ctries* 2013; 7(5): 398-403.

[41] Hari KR, Modi MR, Mochan AH, Modi G. Reduced risk of toxoplasma encephalitis in HIV-infected patients—a prospective study from Gauteng, South Africa. *Int J STD AIDS* 2007; 18(8): 555-8.

[42] Domingos A, Ito LS, Coelho E, Lúcio JM, Matida LH, Ramos AN Jr. Seroprevalence of *Toxoplasma gondii* IgG antibody in HIV/AIDS-infected individuals in Maputo, Mozambique. *Rev Saude Publica* 2013; 47(5): 890-6.

[43] Amuta EU, Amali O, Jacob SE, Houmsou RS. *Toxoplasma gondii* IgG antibodies in HIV/AIDS patients attending hospitals in Makurdi metropolis, Benue State, Nigeria. *Int J Med Biomed Res* 2012; 1(3): 186-92.

[44] Jones JL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB. *Toxoplasma gondii* infection in the United States: seroprevalence and risk factors. *Am J Epidemiol* 2001; 154(4): 357-65.

[45] Coelho RA, Kobayashi M, Carvalho LB Jr. Seroprevalence of IgG antibodies specific to *Toxoplasma gondii* among blood donors in Recife, Northeast Brazil. *Rev Inst Med Trop Sao Paulo* 2003; 45(4): 229-31.

[46] Osunkalu VO, Akunanu SA, Ofomah NJ, Onyiaorah IV, Adediran AA, Akinde RO, et al. Seroprevalence of *Toxoplasma gondii* IgG antibody in HIV-infected patients at the Lagos University Teaching Hospital. *HIV AIDS (Auckl)* 2011; 3: 101-5.

[47] Brockman MA, Kwon DS, Tighe DP, Pavlik DF, Rosato PC, Sela J, et al. IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. *Blood* 2009; 114(2): 346-56.

[48] Kuhn L, Coutsoudis A, Moodley D, Mngqundaniso N, Trabattoni D, Shepard GM, et al. Interferon-gamma and interleukin-10 production among HIV-1-infected and uninfected infants of HIV-1-infected mothers. *Pediatr Res* 2001; 50(3): 412-6.

[49] Zintzaras E, Lau J. Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. *J Clin Epidemiol* 2008; 61(7): 634-45.